BAYER, CONFIDENCE RETURNS IN LEVERKUSEN (BUY; 19% UPSIDE)

17/01/22 -" Investors’ fatigue is the usual summary view about Bayer's (Buy, Germany) share price, five years down the road of the Monsanto acquisition. Value destruction is of outlandish proportions but the ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

17/01/22

Download

You may also be interested by these reports :

23/04/24

Novartis

The Q1 results came in ahead of the consensus as growth was supported by healthy performances across all the focus areas. Consequently, the ...

17/04/24

Virbac

Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...

16/04/24

BB Biotech

Preview: Positive 1Q24 driven by clinical developments of portfolio companies

15/04/24

Idea Kicker

Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue